

# Clinical Oversight Review Board (CORB) Criteria for Prescribing Secukinumab IV (Cosentyx IV)

## Notes:

- Quantity Limits: No (N/A for IV medication)
- ^ Adequate trial is defined as 3 months
- \* Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation
- † Non-modifiable barrier: blindness, hand tremors, limitations in dexterity or cognitive impairment), lacks a caregiver who can perform self-injections, and patient unable to receive self-injection as clinic administered medication (e.g. lack of transportation)

Non-Formulary **secukinumab IV (Cosentyx IV)** requires a clinical review.  
Appropriateness of therapy will be based on the following criteria:

## **Initiation (new start) criteria and criteria for new Kaiser Permanente members already taking the medication who have not been reviewed previously:**

1. Prescriber is a rheumatologist and patient has a diagnosis of psoriatic arthritis
  - Patient is 18 years or older
  - Patient has failed an adequate trial<sup>^</sup>, has an intolerance<sup>\*</sup>, or has a contraindication to methotrexate (methotrexate not required if patient has dactylitis [inflammation of finger or toe] and/or enthesitis [inflammation of the entheses])
  - Patient has tried and failed or has an intolerance<sup>\*</sup> to at least 1 of the following:
    - Infliximab product (unless documented by prescriber that patient is unable to attend infusion appointments)
    - Adalimumab product (criteria based)
  - Patient has a significant non-modifiable barrier<sup>†</sup> that prohibits self-injection
2. Prescriber is a rheumatologist and patient has a diagnosis of ankylosing spondylitis/spondyloarthritis
  - Patient is 18 years or older
  - Patient has tried and failed or has intolerance<sup>\*</sup> to at least 1 of the following:
    - Infliximab product (unless documented by prescriber that patient is unable to attend infusion appointments)
    - Adalimumab product (criteria based)
  - Patient has a significant non-modifiable barrier<sup>†</sup> that prohibits self-injection

kp.org

Revised: 03/07/24  
Effective: 05/16/24

All plans offered and underwritten by  
Kaiser Foundation Health Plan of the Northwest